
Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint
XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly delays time to PSA progression compared to placebo plus ADT Study enrolled 180 men with metastatic hormone-sensitive prostate…